Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Cramer Rosenthal Mcglynn LLC

Cramer Rosenthal Mcglynn LLC grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,706,225 shares of the company’s stock after purchasing an additional 89,031 shares during the period. Elanco Animal Health accounts for 1.9% of Cramer Rosenthal Mcglynn LLC’s portfolio, making the stock its 15th biggest position. Cramer Rosenthal Mcglynn LLC’s holdings in Elanco Animal Health were worth $32,772,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Mariner LLC raised its stake in Elanco Animal Health by 79.6% during the fourth quarter. Mariner LLC now owns 56,193 shares of the company’s stock worth $680,000 after acquiring an additional 24,901 shares during the period. Sterling Capital Management LLC raised its position in shares of Elanco Animal Health by 56.7% during the 4th quarter. Sterling Capital Management LLC now owns 29,414 shares of the company’s stock worth $356,000 after purchasing an additional 10,647 shares during the period. Treasurer of the State of North Carolina lifted its holdings in shares of Elanco Animal Health by 53.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 330,391 shares of the company’s stock worth $4,001,000 after purchasing an additional 115,290 shares during the last quarter. Advisory Services Network LLC boosted its position in Elanco Animal Health by 296.6% during the 4th quarter. Advisory Services Network LLC now owns 75,993 shares of the company’s stock valued at $920,000 after purchasing an additional 56,833 shares during the period. Finally, Invesco Ltd. boosted its position in Elanco Animal Health by 10.6% during the 4th quarter. Invesco Ltd. now owns 536,391 shares of the company’s stock valued at $6,496,000 after purchasing an additional 51,233 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The shares were bought at an average price of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.57% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ELAN. Stifel Nicolaus dropped their target price on Elanco Animal Health from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $14.67.

Elanco Animal Health Stock Up 4.2 %

Elanco Animal Health stock opened at $8.44 on Friday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 21.11, a PEG ratio of 2.50 and a beta of 1.44. The company’s 50-day moving average price is $10.32 and its two-hundred day moving average price is $11.89. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.08 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.